Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
Introduction Prostate cancer is the most common male cancer with one in four developing non-curable metastatic disease. Initial treatment responses to hormonal therapies are transient and further management options lie between (1) further hormone therapy or (2) a non-hormonal approach involving addi...
Saved in:
| Main Authors: | John Marshall, Ruth Wood, Denise Howel, Emma Clark, Rakesh Heer, John Staffurth, Miranda Morton, Shriya Sharma, Holly Fisher, Jenn Walker, Helen Hancock, Rebecca Maier, Ian Pedley, Rob Jones |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/12/e034708.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of androgen receptor splice variants in prostate cancer metastasis
by: Jin Xu, et al.
Published: (2016-10-01) -
Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01) -
Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer
by: Robert D. Marek, et al.
Published: (2024-11-01) -
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
by: Ramesh Narayanan
Published: (2020-07-01) -
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer
by: Larysa Poluben, et al.
Published: (2025-01-01)